| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4088 | Pf-06424439 Mesylate Featured | Potent and selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2) |
|
| DCC4089 | Pf-06655075 | Novel non-brain-penetrant long-acting peptide oxytocin (OT) receptor agonist with increased selectivity for the OT receptor and significantly increased pharmacokinetic stability |
|
| DCC4090 | Pf-06745013 | Novel potent and selective inhibitor of MAP4K4 |
|
| DCC4091 | Pf-06756394 | Novel tyrosine residues probe, rationally targeting active site |
|
| DCC4092 | Pf-06758955 Hydrochloride | Novel potent and selective inhibitor of MAP4K4 |
|
| DC30002 | PF-06835919 Featured | PF-06835919, also known as MDK1846, is a potent ketohexokinase (KHK) inhibitor. PF-06835919 is reported in patent US 20170183328 A1, example 4. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders. |
|
| DCC4094 | Pf-06843195 Prodrug | Novel prdrug of PF-06843195, a potent PI3Kα-selective inhibitor |
|
| DCC4095 | Pf-06939999 | Novel SAM Competitive PRMT5 Inhibitor, Demonstrating Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance |
|
| DCC4096 | Pf1070a | Natural cyclic tetrapeptide HDAC Inhibitor through the inhibition of PfHDAC1 catalytic activity, potently inducing the synthesis of metallothionein |
|
| DCC4097 | Pf-184563 | Potent, selective non-peptidic antagonist of the V1a receptor |
|
| DCC4098 | Pf-3604861 | Novel dual H3/4 histamine receptor antagonist |
|
| DCC4099 | Pf-3837 | Highly selective, extremely potent Mps1 kinase inhibitor |
|
| DCC4100 | Pf-4522654 | Potent and selective 5-HT2C receptor agonist |
|
| DCC4101 | Pf-5177624 | Selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells |
|
| DCC4102 | Pf-543 Hydrochloride Featured | Novel, potent and specific inhibitor of sphingosine kinase-1 (SphK1) |
|
| DCC4103 | pf-5466 | Antimalarial, actively against Plasmodium liver stages |
|
| DCC4104 | Pf-562271 Tosylate | Potent, ATP-competitive, reversible inhibitor of FAK |
|
| DCC4105 | Pf-562771 | Novel potent and selective inhibitor of the activation-loop mutant Kit phosphorylation and tumor growth |
|
| DCC4106 | Pf-68742 | Novel Entry Inhibitor of both CCR5- and CXCR4-Tropic Strains of Human Immunodeficiency Virus Type 1 (HIV-1), Targeting a Novel Site on gp41 |
|
| DCC4107 | Pf-7006 | Highly selective, extremely potent Mps1 kinase inhibitor |
|
| DCC4108 | Pf-alkyne | Novel fluorophosphonate-based probe, specifically and covalently reacts with the tyrosine-111 residue of the Schistosoma japonicum GST (sjGST) tag, rapidly and site-selectively immobilizes sjGST fusion proteins |
|
| DCC4109 | Pf-cbp/brd4 | Novel dual CBP/p300 and BRD4 bromodomain inhibitor, downregulating IL-6, IL-ß and IFN-ß in macrophages |
|
| DCC4110 | Pfi-7n | Negative control for PFI-7 (GLXC012596) |
|
| DCC4111 | Pfkrs1-in-5 | Novel selective inhibitor of both Plasmodium and Cryptosporidium lysyl-tRNA synthetase, clearing parasites from mouse models of malaria and cryptosporidiosis infection. |
|
| DCC4112 | Pfn1-in-c1 | Novel inhibitor of Profilin1 (Pfn1), reducing the overall level of cellular filamentous (F)-actin, slowing EC migration and proliferation, and inhibiting the angiogenic ability of EC both in vitro and ex vivo |
|
| DCC4113 | Pfn1-in-c2 | Novel inhibitor of Profilin1 (Pfn1), reducing the overall level of cellular filamentous (F)-actin, slowing EC migration and proliferation, and inhibiting the angiogenic ability of EC both in vitro and ex vivo |
|
| DCC4114 | Pg490-88 | Water soluble derivative pro-drug of PG490 (triptolide) |
|
| DCC4115 | Pg-928310 | Novel anti-HIF-1alpha agent |
|
| DCC4116 | Pg97-269 Tfa Salt | Potent and selective antagonist of the VIP1 receptor, inhibiting competitively effect of VIP on the VIP1 receptor mediated stimulation of adenylate cyclase activity with Ki values respectively of 15 ± 5 nM and 2 ± 1 nM for the rat and human VIP1 receptor |
|
| DCC4117 | Pgam1 Inhibitor Kh2 | Novel allosteric PGAM1 inhibitor, showing efficacious in multiple preclinical models of pancreatic ductal adenocarcinoma (PDAC), especially with high PGAM1 expression |
|
